This announcement was really just advising the Trial Expansion is now open, the contined Complete Response is great and is rightfully prominently announced as it is very good news.
Additionally, Imugene confirms its Bile Tract Cancer Expansion part of the trial has now cleared its first cohort, after the first
three patients were evaluated for safety and experienced no dose limiting toxicities (DLTs). It is now open for full enrolment of up to 10 patients.
Ann: Complete Response in MAST Study Maintained Over Two Years, page-30
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |